



# Kabra Drugs Limited

CIN NO : L02423MP1989PLC005438

Corp. Off : No.3, 2nd Floor, Swaminathan Street, West Mambalam, Chennai - 600 033.

---

Date: 14 June 2026

To,  
BSE Limited  
Phiroze Jeejeebhoy Towers  
21<sup>st</sup> Floor, Dalal Street  
Mumbai – 400001

**BSE Scrip Code: 524322**

**Subject: Press Release on Letter of Intent from Government of Chhattisgarh for ₹200 Crore Pharmaceutical Manufacturing Project**

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith Press Release on Letter of Intent from Government of Chhattisgarh for ₹200 Crore Pharmaceutical Manufacturing Project

The above can also be accessed on the website of the Company at [www.kabradrugs.com](http://www.kabradrugs.com)

Kindly take the aforesaid information on record and oblige.

Thanking you,

Yours sincerely,

**For Kabra Drugs Limited**

**Nanjappan Aravind**  
**Managing Director**  
**DIN: 01895602**





## **Kabra Drugs Limited Receives Letter of Intent from Government of Chhattisgarh for ₹200 Crore Pharmaceutical Manufacturing Project**

**Chennai, India: June 13, 2026**

Kabra Drugs Limited (BSE: KABRADG | INE323K01017), a research-driven pharmaceutical company focused on specialty formulations, injectables, and APIs, announced that it has received a Letter of Intent (LOI) from the Government of Chhattisgarh for the proposed establishment of a pharmaceutical manufacturing facility at Nava Raipur Pharma Park, Chhattisgarh.

### **Project Highlights**

<i>Particulars</i>	<i>Details</i>
<i>Proposed Investment</i>	<i>Approximately ₹200 Crore</i>
<i>Project Location</i>	<i>Nava Raipur Pharma Park, Chhattisgarh</i>
<i>Nature of Project</i>	<i>Pharmaceutical Manufacturing Facility and Related Healthcare Manufacturing Activities</i>
<i>Employment Generation</i>	<i>Approximately 250 Direct and Indirect Opportunities</i>
<i>Authority</i>	<i>Government of Chhattisgarh</i>
<i>Date of LOI Receipt</i>	<i>June 12, 2026</i>

### **Strategic Significance of the Project**

- The proposed investment marks a significant milestone in Kabra Drugs Limited's long-term expansion strategy and is expected to substantially enhance the Company's manufacturing footprint. The project aims to strengthen operational capabilities,

expand production capacity, and position the Company to capitalize on emerging opportunities in the pharmaceutical and healthcare manufacturing sectors.

- The facility is proposed to be established at Nava Raipur Pharma Park; a strategically located pharmaceutical manufacturing hub being developed by the Government of Chhattisgarh. The project is expected to create approximately 250 direct and indirect employment opportunities, contributing to regional economic development while supporting the Company's future growth plans.
- The Company expects to benefit from applicable state government policies, incentives, approvals, and support mechanisms, subject to sanction orders and compliance with statutory requirements. The investment proposal remains subject to execution of definitive agreements and receipt of necessary approvals and sanctions.

**Commenting on the receipt of the Letter of Intent, Mr. N. Aravind, Managing Director of Kabra Drugs Limited, said:** *"The receipt of the Letter of Intent from the Government of Chhattisgarh marks an important milestone in Kabra Drugs Limited's growth journey. The proposed ₹200 crore investment at Nava Raipur Pharma Park is aligned with our vision of expanding our manufacturing capabilities and strengthening our presence in the pharmaceutical sector.*

*This project is expected to enhance our operational footprint, create employment opportunities, and support our long-term growth strategy. We remain committed to building a future-ready pharmaceutical platform focused on quality, innovation, and sustainable value creation for all stakeholders."*

### **About Kabra Drugs Limited**

Kabra Drugs Limited (Kabra Drugs) is a research-driven pharmaceutical company focused on specialty formulations, injectables, and APIs. Founded with the vision of making quality healthcare science-driven and accessible, the Company is committed to delivering safe,

effective, and globally competitive pharmaceutical solutions. Backed by WHO-GMP aligned systems, advanced manufacturing capabilities, and innovation-led processes, Kabra Drugs continues to strengthen its presence across key therapeutic areas while maintaining a strong focus on quality, integrity, and responsible growth.

### **Disclaimer**

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

### **For Further Information Please Contact Corporate Communication Advisor**



*AKMIL Strategic Advisors Private Limited*  
*Mr. Milind Apte – Director*  
*milind@akmiladvisors.com*  
*+91 98209 41925*  
*www.akmiladvisors.com*